Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

ClinicalTrials.gov ID: NCT04305834

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04305834. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.

Study identification

NCT ID: NCT04305834
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: City of Hope Medical Center; Other
Enrollment: 43 participants

Conditions and interventions

Conditions

Interventions

Abemaciclib Drug
Questionnaire Administration Other

Drug · Other

Eligibility (public fields only)

Age range: 70 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 5, 2020 (Actual)
Primary completion: May 21, 2027 (Estimated)
Completion: May 21, 2027 (Estimated)
Last update posted: Oct 16, 2026

2020 – 2027

United States locations

U.S. sites: 6
U.S. states: 3
U.S. cities: 6

Facility	City	State	ZIP	Site status
City of Hope Medical Center	Duarte	California	91010	Recruiting
City of Hope at Irvine Lennar	Irvine	California	92618	Recruiting
City of Hope at Long Beach Elm	Long Beach	California	90813	Recruiting
City of Hope South Pasadena	South Pasadena	California	91030	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14203	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04305834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 16, 2026 · Synced Nov 12, 2026